ERBB2 and neoplasm: For example, by using this mouse model, Goel et al. showed that cyclin D1/Cyclin-dependent kinase 4 (CDK4) mediated resistance to human epidermal growth factor 2 (HER2)-targeted therapy and that CDK4/6 inhibitors delayed a HER2 positive tumor relapse [27].